CN101420944A - 用于优化替代疗法和扩展用于成瘾的整体疗法的药物集的新型药物组合物 - Google Patents

用于优化替代疗法和扩展用于成瘾的整体疗法的药物集的新型药物组合物 Download PDF

Info

Publication number
CN101420944A
CN101420944A CNA2007800136067A CN200780013606A CN101420944A CN 101420944 A CN101420944 A CN 101420944A CN A2007800136067 A CNA2007800136067 A CN A2007800136067A CN 200780013606 A CN200780013606 A CN 200780013606A CN 101420944 A CN101420944 A CN 101420944A
Authority
CN
China
Prior art keywords
pharmaceutical composition
composition according
prodopaminergic
amisulpride
indirect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800136067A
Other languages
English (en)
Chinese (zh)
Inventor
M·桑切斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trimaran Ltd
Original Assignee
Trimaran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimaran Ltd filed Critical Trimaran Ltd
Publication of CN101420944A publication Critical patent/CN101420944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800136067A 2006-02-17 2007-02-19 用于优化替代疗法和扩展用于成瘾的整体疗法的药物集的新型药物组合物 Pending CN101420944A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRPCT/FR06/000372 2006-02-17
PCT/FR2006/000372 WO2007096489A1 (fr) 2006-02-17 2006-02-17 Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions

Publications (1)

Publication Number Publication Date
CN101420944A true CN101420944A (zh) 2009-04-29

Family

ID=37054597

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800136067A Pending CN101420944A (zh) 2006-02-17 2007-02-19 用于优化替代疗法和扩展用于成瘾的整体疗法的药物集的新型药物组合物

Country Status (7)

Country Link
US (1) US20110039834A1 (enExample)
EP (2) EP1988883A1 (enExample)
JP (1) JP2009526833A (enExample)
CN (1) CN101420944A (enExample)
AU (1) AU2007216255A1 (enExample)
CA (1) CA2642561A1 (enExample)
WO (2) WO2007096489A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441067A (zh) * 2011-08-18 2017-12-08 拜欧帝力威瑞科学有限公司 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置
CN112245434A (zh) * 2020-11-09 2021-01-22 深圳善康医疗健康产业有限公司 一种纳曲酮和利培酮复方缓释组合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CA3175428A1 (en) * 2020-04-13 2021-10-21 aiberry, Inc. Multimodal analysis combining monitoring modalities to elicit cognitive states and perform screening for mental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1644335A4 (en) * 2003-07-11 2008-06-04 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
EP1670460B1 (en) * 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
PT1697371E (pt) * 2003-12-19 2007-08-03 Bristol Myers Squibb Co Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
FR2877573B1 (fr) * 2004-11-05 2007-02-02 Debussy Holding Sa Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441067A (zh) * 2011-08-18 2017-12-08 拜欧帝力威瑞科学有限公司 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置
CN112245434A (zh) * 2020-11-09 2021-01-22 深圳善康医疗健康产业有限公司 一种纳曲酮和利培酮复方缓释组合物
WO2022095203A1 (zh) * 2020-11-09 2022-05-12 深圳善康医疗健康产业有限公司 一种纳曲酮和利培酮复方缓释组合物
CN116710097A (zh) * 2020-11-09 2023-09-05 深圳善康医药科技股份有限公司 一种纳曲酮和利培酮复方缓释组合物
EP4233844A4 (en) * 2020-11-09 2023-10-25 Shenzhen Sciencare Pharmaceutical Co., Ltd. SUSTAINED RELEASE COMPOSITION FROM A NALTREXONE AND RISPERIDONE COMBINATION

Also Published As

Publication number Publication date
EP1988883A1 (fr) 2008-11-12
US20110039834A1 (en) 2011-02-17
JP2009526833A (ja) 2009-07-23
AU2007216255A1 (en) 2007-08-23
WO2007096489A1 (fr) 2007-08-30
EP2015739A1 (fr) 2009-01-21
WO2007093909A1 (fr) 2007-08-23
CA2642561A1 (fr) 2007-08-23

Similar Documents

Publication Publication Date Title
Dodd et al. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Marona-Lewicka et al. Reinforcing effects of certain serotonin-releasing amphetamine derivatives
Gamberino et al. Neurobiology of tobacco smoking and other addictive disorders
JP2002522383A (ja) 嗜癖又は嗜癖関連行動の治療
US20150051192A1 (en) Blocking of cue-induced drug reinstatement
CN101420944A (zh) 用于优化替代疗法和扩展用于成瘾的整体疗法的药物集的新型药物组合物
Arias et al. Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion
Santiago et al. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum
MD et al. Pharmacokinetics and pharmacodynamics of abused drugs
JP2004501105A (ja) 禁煙の促進方法
Trillat et al. Effects of WAY 100635 and (−)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses
Nouri et al. Concomitant abuse of methadone and methamphetamine could impair spatial learning and memory in male rats
Farré et al. Addiction to hallucinogens, dissociatives, designer drugs and “legal highs”
US20080090895A1 (en) Novel Pharmaceutical Composition And Their Uses Thereof For Controlling The Different Forms Of Addiction To Drugs
CN103877096B (zh) 盐酸氯卡色林在制备抑制阿片类物质成瘾和戒断反应的药物中的应用
Serani et al. Mechanisms Of Opioid-Induced Hyperalgesia: Implications For Chronic Pain Management
Herian Pharmacological action of LSD: LSD effect on the neurotransmission and animal behavior
Jenkins Pharmacokinetics of specific drugs
Davis et al. Drug interactions involving the drugs of abuse
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
Ritz Molecular mechanisms of addictive substances
CN104666305B (zh) 一种高选择性5‑羟色胺5‑ht2c受体激动剂way163909的用途
Kramer Evidence for the involvement of the serotonin uptake transporter and the serotonin-2 receptor in the activation of protein kinase C (PKC) by substituted amphetamines in the adult rodent brain
Raygada The Role of hypothalamic insulin and dopamine in the anorectic effect of cocaine and d-amphetamine
Lakoski et al. The Advantages and Limitations of Calmatives for Use as a Non-Lethal

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090429